Sofosbuvir and Velpatasvir are pharmaceutical compounds used to treat chronic hepatitis C (HCV) infections. Sofosbuvir is a nucleotide analogue inhibitor and Velpatasvir is a differentiated NS5A inhibitor. The combination of both is used to directly target HCV replication. Sofosbuvir Velpatasvir Tablets, marketed as Epclusa, are designed to treat genotypes 1-6 of HCV, excluding genotype 3. The treatment works by stopping the virus from multiplying, allowing the body to eliminate the infection. Epclusa is typically prescribed by a healthcare provider and is available in 400mg/100mg strength tablets.